HTI-501: Additional Phase II data

Data from 36 evaluable women with moderate to severe edematous fibrosclerotic panniculopathy in the Phase II portion of a blinded, Mexican Phase I/II trial showed that subcutaneous HTI-501 met the primary endpoint of a greater mean improvement in physician-assessed cellulite appearance from baseline to day 28 vs. vehicle controls (53% vs. 33%, p=0.005). Additionally, HTI-501 led to significantly greater mean improvements in physician-assessed cellulite appearance at 3 months (57% vs. 43%, p<0.001) and 6 months (61% vs. 43%, p<0.001) vs. vehicle controls. ...